SEC Form 8-A12B filed by BriaCell Therapeutics Corp.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF
THE SECURITIES EXCHANGE ACT OF 1934
BriaCell Therapeutics Corp.
(Exact name of registrant as specified in its charter)
British Columbia | 47-1099599 | |
(State
or other jurisdiction of incorporation or organization) |
(I.R.S.
Employer Identification No.) | |
Suite 300 – 235, 15th Street, West Vancouver, BC Canada | V7T 2X1 | |
(Address of principal executive offices) | (Zip Code) |
Securities to be registered pursuant to Section 12(b) of the Act:
Title of each class to be so registered |
Name of each exchange on which each class is to be registered | |
Warrants to purchase common shares, no par value |
The Nasdaq Stock Market LLC |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐
If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐
Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333- 333-286670
Securities to be registered pursuant to Section 12(g) of the Act: None.
INFORMATION REQUIRED IN REGISTRATION STATEMENT
Item 1. Description of Registrant’s Securities to be Registered.
The description of the warrants to purchase common shares of BriaCell Therapeutics Corp. (the “Registrant”) under the heading “Description Of Securities—Warrants to be Issued in this Offering” in the prospectus included in the Registrant’s Registration Statement on Form S-1 (File No. 333-286670), filed with the Securities and Exchange Commission on April 22, 2025, as amended on April 23, 2025, including the exhibits thereto (the “Registration Statement”), is hereby incorporated by reference. Any form of prospectus that constitutes part of the Registration Statement and is subsequently filed by the Registrant pursuant to Rule 424(b) under the Securities Act of 1933, as amended, shall be deemed to be incorporated by reference herein.
Item 2. Index to Exhibits.
The following exhibits have been filed as exhibits to the Registration Statement and are incorporated herein by reference:
SIGNATURES
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
BriaCell Therapeutics Corp. | ||
Date: April 24, 2025 | By: | /s/ William V. Williams |
William V. Williams | ||
Chief Executive Officer |